GlassScriptPhysician profile
Gina Grove
NPI 1659332526
$6,102.08
in general payments reported to CMS, 2019-2025
38 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $146 · 2021: $482 · 2022: $692 · 2023: $1,281 · 2024: $1,312 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,840 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,839.99 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,209.50 | 2019-2025 | |
| Novo Nordisk INC | $1,062.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $408.11 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $375.75 | 2019-2025 | |
| Astellas Pharma US INC | $369.74 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $307.90 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $304.03 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $272.57 | 2019-2023 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.36 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $173.01 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Abbott Laboratories | $172.65 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $136.76 | 2024-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $124.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.60 | 2019-2022 | |
| Exact Sciences Corporation | $93.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Grove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.